The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 571-574

  Bayram, Ibrahim ^a   Erbey, Fatih ^a   Celik, Nilgun ^b   Nelson, Jeffrey L ^c   Tanyeli, Atila ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Home Care Nurse   (Turkey)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Cachexia; Cancer; Children; Eicosapentaenoic acid; N 3 fatty acids; Nutrition

Indexed keywords

ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PROTEIN;

ARTICLE; BODY MASS; BODY WEIGHT; CACHEXIA; CANCER CHEMOTHERAPY; CHILD; CHILD NUTRITION; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; FEBRILE NEUTROPENIA; FEMALE; FOOD INTAKE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DIET; REMISSION; SOLID TUMOR; WEIGHT REDUCTION; DRUG EFFECT; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

CHILD; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; NEOPLASMS; PROTEINS; WEIGHT LOSS;

EID: 63649141944     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21852     Document Type: Article

References (30)

1. Argiles J, Busquets S, Garcia-Martinez C, et al. Mediators involved in the cancer anorexia-cachexia syndrome: Past, present, and future. Nutrition 2005;21:977-985.
2. Bauer J, CapraS. Comparison of a malnutrition screening tool with subjective global assessment in hospitalized patients with cancer- sensitivity and specificity. Asia Pac J Clin Nutr 2003;12:257 -260.
3. Ottery F. Supportive nutritional management of the patient with pancreatic cancer. Oncology 1996;10:26-32.
4. Evans WK, Nixon DW, Daly JM, et al. A randomized trial of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987;5:113-124.
5. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol 1993;11:2043-2049.
6. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mono- nuclear cells. N Engl J Med 1989;320:265-271.
7. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial. Cancer 1998;82:395 -402.
8. Wigmore SJ, Rearon KCH, Maingay JP, et al. Down-regulation of the acute phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is medicated via suppression of interleukin-6. Clin Sci 1997;92:215-221.
9. Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001;61:3604- 3609.
10. Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, et al. n-3 fatty acids, cancer and cachexia: A systematic review of the literature. Br J Nutr 2007;97:823-831.
11. Moses AW, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004;90:996-1002.
12. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-86.
13. Guarcello M, Riso S, Andrea FD. EPA-enriched oral nutritional support in patients with lung cancer: Effects on nutritional status and quality of life. Nutr Therapy Metab 2006;24:168-175.
14. Weed HG, Gaff RL, Ferguson ML, et al. Impact of a protein and energy dense nutritional supplement containing eicosapentaenoic acid on weight-losing patients with head and neck cancer. J Clin Oncol 2005 ASCO Annu Meeting Proc 23:8112.
15. Read JA, Beale PJ, Volker DH, et al. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: A phase II trial. Support Care Cancer 2007; 15:301 -3307.
16. Dunlop R. Clinical epidemiology of cancer cachexia. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients, Vol. 5. Oxford: Oxford University press; 1996. pp. 76-82.
17. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-871.
18. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapyA pilot study. Support Care Cancer 2005;13:270-274.
19. Fearon K, von Meyenfeldt M, Moses A, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomized double blind trial. Gut 2003;52:1479-1486.
20. Edington J, Hollingsworth M, Rhoades L, et al. Oral nutritional supplement flavor preferences of weight-losing patients with cancer. Proc Nutr Soc 2002;61:33A.
21. Richardson R, Ferguson M, Ried K, et al. A protein and energy dense, n-3 fatty acid enriched oral nutritional supplement improves dietary intake in patients with cancer cachexia. Proc Nutr Soc 2002;61:27A.
22. Andreyev HJN, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503 -509.
23. Silvestri G, Pritchard R, Welch H. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. Br Med J 1998;317:771 -775.
24. Burns CP, Spector AA. Biochemical effects of lipids on cancer therapy. J Nutr Biochem 1994;5:114-123.
25. Mantovani G, Maccio A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995; 25:455-461.
26. Fearon K, Carter DC. Cancer cachexia. Ann Surg 1988;208:1 -5.
27. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-563.
28. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211 -1227.
29. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. J Parenteral Enteral Nutr 1992;16:50S-55S.
30. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991;41:103 -107.